Charles River Laboratories Intl. Inc (NYSE:CRL) to Post FY2019 Earnings of $6.57 Per Share, William Blair Forecasts

Charles River Laboratories Intl. Inc (NYSE:CRL) – Stock analysts at William Blair raised their FY2019 EPS estimates for shares of Charles River Laboratories Intl. in a research report issued on Wednesday, November 6th. William Blair analyst J. Kreger now expects that the medical research company will post earnings per share of $6.57 for the year, up from their previous estimate of $6.55. William Blair also issued estimates for Charles River Laboratories Intl.’s Q4 2019 earnings at $1.85 EPS, Q2 2020 earnings at $1.90 EPS, FY2020 earnings at $7.59 EPS, FY2021 earnings at $8.65 EPS, FY2022 earnings at $9.74 EPS and FY2023 earnings at $10.97 EPS.

Several other analysts also recently issued reports on the company. Bank of America downgraded Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price target on the stock. in a research note on Friday, October 18th. SunTrust Banks lifted their price target on Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, September 16th. ValuEngine downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. UBS Group dropped their price target on Charles River Laboratories Intl. from $147.00 to $145.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, Credit Suisse Group set a $138.00 price target on Charles River Laboratories Intl. and gave the company a “hold” rating in a research note on Friday, September 13th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $150.31.

Shares of CRL traded up $3.09 during midday trading on Friday, hitting $130.46. The stock had a trading volume of 20,266 shares, compared to its average volume of 304,375. The company has a 50 day simple moving average of $132.31 and a two-hundred day simple moving average of $133.44. Charles River Laboratories Intl. has a twelve month low of $103.00 and a twelve month high of $149.07. The firm has a market cap of $6.23 billion, a price-to-earnings ratio of 21.62, a price-to-earnings-growth ratio of 2.00 and a beta of 1.08. The company has a debt-to-equity ratio of 1.47, a current ratio of 1.59 and a quick ratio of 1.38.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.64 by $0.05. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The firm had revenue of $668.00 million for the quarter, compared to the consensus estimate of $674.08 million. During the same quarter last year, the business posted $1.53 EPS. The company’s revenue for the quarter was up 14.1% on a year-over-year basis.

A number of institutional investors have recently bought and sold shares of CRL. Squar Milner Financial Services LLC boosted its holdings in shares of Charles River Laboratories Intl. by 253.2% during the third quarter. Squar Milner Financial Services LLC now owns 219 shares of the medical research company’s stock worth $28,000 after acquiring an additional 157 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in shares of Charles River Laboratories Intl. during the third quarter worth approximately $33,000. Flagship Harbor Advisors LLC boosted its holdings in shares of Charles River Laboratories Intl. by 132.1% during the second quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock worth $45,000 after acquiring an additional 181 shares during the period. CWM LLC boosted its holdings in shares of Charles River Laboratories Intl. by 75.9% during the third quarter. CWM LLC now owns 387 shares of the medical research company’s stock worth $51,000 after acquiring an additional 167 shares during the period. Finally, Steward Partners Investment Advisory LLC bought a new stake in shares of Charles River Laboratories Intl. during the second quarter worth approximately $69,000. Institutional investors and hedge funds own 94.31% of the company’s stock.

In other news, insider David Ross Smith sold 1,249 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $130.36, for a total value of $162,819.64. Following the completion of the transaction, the insider now owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.80% of the stock is owned by company insiders.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: The primary rules of Elliott Wave theory

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply